Attralus is pioneering a transformative approach to treating systemic amyloidosis through its proprietary pan-amyloid removal (PAR) therapeutics. These novel biologics are designed to specifically bind to and eliminate toxic amyloid deposits that accumulate in vital organs, addressing a significant unmet medical need in a disease that is often underdiagnosed and lacks effective treatment options. The lead candidate, AT-02, is a humanized IgG1 monoclonal antibody fused with a pan-amyloid binding peptide, enabling it to target multiple types of amyloid deposits. This innovative design not only facilitates the removal of existing amyloid but also stimulates the immune system to enhance the phagocytic activity of macrophages, thereby promoting the clearance of amyloid from the body.

In addition to its therapeutic candidates, Attralus is also developing the first amyloidosis-specific imaging agent, AT-01, which utilizes the same pan-amyloid targeting mechanism. This imaging agent aims to provide comprehensive visualization of amyloid deposits across various organs, enabling better diagnosis and monitoring of the disease. The company’s approach extends beyond systemic amyloidosis, as it is also exploring applications in neurodegenerative diseases by targeting multiple forms of amyloid, such as those associated with Alzheimer’s and Parkinson’s diseases. By focusing on the underlying pathology of amyloidosis and related disorders, Attralus is positioned to significantly advance treatment paradigms and improve patient outcomes.

United States

Attralus is a clinical stage biopharmaceutical company focused on creating transformative medicines to improve the lives of patients with systemic amyloidosis. Our proprietary pan-amyloid removal (PAR) therapeutics are designed to directly bind to and remove toxic amyloid in organs and tissues. By targeting the universal disease-causing pathology in all systemic amyloidosis diseases, PAR therapeutics have the potential to treat and reverse disease in patients with all types and stages of systemic amyloidosis.

Attralus

Company Details